Research Banner Thierry

About us

The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research centre at the University of Oxford supported by Parkinson’s UK with funds from The Monument Trust, one of the Sainsbury Family Charitable Trusts.

Established in February 2010, the Oxford Parkinson’s Disease Centre (OPDC) brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.

Our world-class research centre was formed to understand the earliest events in the development of Parkinson’s and create animal models with greater relevance to the disease, ultimately with a view to identifying the changes which occur before the symptoms become apparent.

Our programme targets the molecular pathways to Parkinson’s in order to:

  1. Understand the progression of Parkinson’s
  2. Predict the onset of Parkinson’s
  3. Identify potential drug targets for Parkinson’s
  4. Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
  • Watch the video below to learn more about OPDC's research

 

Selected Publications

News

Sleep study seeks people with Parkinson's and/or RBD

Sleep study seeks people with Parkinson's and/or RBD

Posted 14/11/2018

Researchers at OPDC are embarking on a new five-year study looking at the links between a condition known as Rapid Eye Movement Sleep Behaviour Disorder (RBD) and Parkinson’s. Funded by the NIHR Oxford Biomedical Research Centre. The study seeks to improve the remote diagnosis and monitoring of sleep problems at home and is currently looking for people with Parkinson's and RBD to take part. RBD is a sleep problem where the switch that ...


Experimental cancer drug shows promise for Parkinson’s

Experimental cancer drug shows promise for Parkinson’s

Posted 29/11/2018

A drug originally developed for prostate cancer may have exciting potential for treating Parkinson’s, according to our new research published in Cell Stem Cell. The study, funded by Parkinson’s UK, suggests that the drug, tasquinimod, which is not yet on the market, works by controlling genes that may cause Parkinson’s. This happens when the drug interacts with a protein inside brain cells. The team here at the Oxford Parkinson’s Disease ...


Precision medicine for Parkinson’s, how close are we?

Precision medicine for Parkinson’s, how close are we?

Posted 28/11/2018

OPDC Medical statistician Michael Lawton has been working on a collaboration with the OPDC and Tracking Parkinson's cohorts to better define Parkinson's. His research has revealed 4 possible subtypes of the condition.

Click here to sign up to the OPDC News Mailing list

Seminars/Events

Elisa Greggio 13 Feb 2019

Elisa Greggio 13 Feb 2019

Posted 27/11/2018

Dr. Elisa Greggio is a molecular physiologist in the Department of Biology at the University of Padova, Italy. RESEARCH INTERESTS: Genetic forms of dominant Parkinson's.Mitochondrial function, axonal transport and cellular pathways in Parkinson's.Biochemical properties of Leucine-rich repeat kinase 2 (LRRK2).Oxidative stress in Parkinson's. http://www.bio.unipd.it/~bubacco/html/elisa_greggio.html  

Kirsten Harvey 27 Mar 2019

Kirsten Harvey 27 Mar 2019

Posted 27/11/2018

My research has focused on two main aspects of neurobiology, the pathogenesis of Parkinson’s and trapping and accumulation of inhibitory receptors at synapses. In my laboratory, we employ cell biological, biochemistry and proteomic techniques in an effort to: i) discover how pathogenic mutations in PARK genes lead to neuronal death, ii) uncover new leads for genetic analysis, and iii) identify new therapeutic targets for disease modifying ...

 

   Find us on Facebook  
OUH TrustBRC logoNIHR